LONDON (dpa-AFX) - Novoheart said that it has collaborated with AstraZeneca to develop the world's first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.
Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide in 2017, with an increasing trend in prevalence. The annual global economic burden of HF is estimated at over US$100 billion.
In collaboration with the Cardiovascular, Renal and Metabolism therapy area of AstraZeneca, the initial phase of the project aims to establish a new in vitro model, leveraging Novoheart's proprietary 3-D human ventricular cardiac organoid chamber (hvCOC) technology, that reproduces key phenotypic characteristics of HFpEF.
Novoheart will exclusively own the intellectual property rights to the newly developed HFpEF hvCOC model.
Copyright RTT News/dpa-AFX